Scandion Oncology () | Spotlight

Home

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Scandion Oncology

Quotes for Scandion Oncology

Right Now

+/-
%: 0,00%
Latest
High
Low
Volume: 0
Turnover (CUR): 0

Board

CEO

Bo Rode Hansen

Chairperson of the Board

Peter Høngaard

Board

Annie Rasmussen
Bo Hansen
Carl Borrebäck
Christian Vinding Thomsen
Jørgen Bardenfleth
Thomas Feldthus

Articles of association

News

2021-01-28 21:35:07 Scandion Oncology adjusts the PANTAX pancreatic cancer study
2021-01-23 13:40:56 Scandion Oncology has finalized the first 12 patients in the CORIST study
2021-01-19 16:53:53 Spotlight: Market Notice 11/21 - Scandion Oncology A/S will be delisted after close of the market on February 2, 2021
2021-01-19 15:34:24 Scandion Oncology approved for listing on Nasdaq First North Growth Market Sweden on 3 February 2021
2021-01-07 08:53:33 Spotlight: Market Notice 5/21– Last day of trading in Scandion Oncology A/S’s BTA

Show More

News agencies

2021-07-05 16:48:27 MarketWire: Scandion Oncologys topchef køber 10.800 aktier
2021-06-24 08:43:02 MarketWire: Dansk biotekselskab med positive delresultater med lægemiddelkandidat
2021-03-19 12:21:01 MarketWire: Scandion Oncology appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations
2021-02-18 08:27:24 MarketWire: Year-end Report 2020: Scandion Oncology is poised for the future
2021-02-02 07:01:00 Finwire: Scandion Oncology har idag sista handelsdag på Spotlight före byte till First North

Show More

Analysis

2018-10-09 SvD Börsplus: Svår att motstå?

Videos

Annual reports, prospectus etc.